The addition of anti-PD-L1 antibodies to platinum-based chemotherapy has significantly improved OS in metastatic, non-oncogene-addicted NSCLC, regardless of PD-L1 expression [33,34], and in NSCLC without EGFR/ALK/ROS1 alterations [35]. Here, ALK is linked to non-small cell lung carcinoma.